ERBB2 and breast carcinoma: Therefore, we used targeted capture sequencing to analyse circulating tumour DNA (ctDNA) to determine the frequency and spectrum of HER2 mutations in patients with advanced breast cancer and to analyse the relationships between HER2 mutations and their effects on the efficacy of anti-HER2 therapies.